We use both our own and third-party cookies for statistical purposes and to improve our services. If you continue to browse, we consider that you accept the use of these.
 In News

Steven Daniel joins Cofactor Genomics as Vice President of Business Development

— Leading Cofactor’s commercial efforts to grow the Predictive Immune Modeling market   —

San Francisco, June 20, 2019 (REPORTABLE) — Cofactor Genomics today announced the appointment of Steven Daniel, PhD as Vice President of Business Development, overseeing the development and execution of the company’s sales strategy and sales management. Dr. Daniel comes to Cofactor from ArcherDX where he was Senior Director, Applied Sciences and Business Development.

“Given Steve’s multiple successes in leading commercial launches of immune-centric tools and diagnostics made him well suited for the role of VP of Business Development at Cofactor” said Jarret Glasscock, CEO of Cofactor. “This experience paired with Steve’s shared excitement around fully enabling precision medicine in the immune-oncology space bodes well for both team Cofactor and the industry as a whole”.

Dr. Daniel has a breadth of experience in the area of immune-related technologies, with 5 issued patents and over 23 years of biotechnology and genomics industry experience, including clinical genomics. Having brought multiple technologies to market from invention through launch, Dr. Daniel will be a key player in growing the field of Predictive Immune Modeling by capitalizing on Cofactor’s recently announced clinical-certifications and corporate partnerships.

Dr. Daniel’s past experiences include: Senior Director of Pharma/CRO Business Development at ArcherDX, VP of Sales at Genos/Nantomics, Senior Director of Pharma Business Development at Adaptive Biotechnologies, and multiple earlier commercial positions (including posts at Life Technologies, AltheaDX, Metabolon, Affymetrix, and more).

“I am thrilled to have the opportunity to help bring these enabling biomarker discovery tools into clinical application for immune-oncology therapeutic development.  Though single-analyte tests have brought incremental gains in therapeutic prediction, Cofactor’s multidimensional biomarker platform will inform better therapeutic decisions in selecting the right treatment for the right patient at the right time,” noted Dr. Daniel.

Dr. Daniel represents the latest hire for Cofactor’s growing team. Other open positions may be found at; https://cofactorgenomics.com/careers/


About Cofactor Genomics

Cofactor Genomics is a Predictive Immune Modeling company. Cofactor has leveraged its experience as one of the first CAP-certified, clinical RNA sequencing laboratories to develop new methods that better characterize disease. Instead of searching for isolated, single-analyte biomarkers, Cofactor’s products create multidimensional biomarkers that better capture the complex immune response. Cofactor has spent years pioneering the molecular and machine learning tools to build a database of Health Expression Models, enabling advancements in Predictive Immune Modeling. Through their molecular, informatic, and database tools, Cofactor Genomics enables their partners to deliver more expedient, cost effective, and successful clinical trials. Find out more about how Cofactor Genomics is revolutionizing biomarker discovery and immuno-oncology at cofactorgenomics.com.


Media Contact:

Terri Clevenger
Continuum Health Communications/ICR
[email protected]
(203) 856-4326

Recent Posts

Start typing and press Enter to search